SBIO
ALPS Medical Breakthroughs ETF
Price Chart
Latest Quote
$55.11
+0.86 (+1.59%)
Current Price
| Previous Close | $54.25 |
| Open | $56.14 |
| Day High | $56.14 |
| Day Low | $54.75 |
| Volume | 13,271 |
Fund Information
| Net Assets | $161.79M |
| Expense Ratio | 0.50% |
| Category | Health |
| Fund Family | ALPS |
| Net Asset Value | $55.21 |
| Premium/Discount | -0.19% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $52.67 |
| SMA50 | $53.94 |
| SMA200 | $48.82 |
| RSI | 52.21 |
| ATR | 1.7156 |
| Rel Volume | 0.70 |
Performance History
| Week | +5.80% |
| Month | +8.23% |
| Quarter | +11.39% |
| 6 Months | +9.31% |
| YTD | +9.87% |
| Year | +81.84% |
| 3 Years | +70.03% |
| 5 Years | +14.82% |
| 10 Years | +156.38% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $55.11 | 15,100 |
| 2026-06-17 | $54.25 | 9,000 |
| 2026-06-16 | $53.26 | 10,100 |
| 2026-06-15 | $53.50 | 10,200 |
| 2026-06-12 | $52.76 | 36,000 |
| 2026-06-11 | $52.09 | 15,900 |
| 2026-06-10 | $50.52 | 10,600 |
| 2026-06-09 | $51.50 | 23,000 |
| 2026-06-08 | $50.34 | 24,800 |
| 2026-06-05 | $50.52 | 14,200 |
| 2026-06-04 | $52.22 | 15,200 |
| 2026-06-03 | $51.02 | 14,200 |
| 2026-06-02 | $50.31 | 36,500 |
| 2026-06-01 | $52.81 | 54,200 |
| 2026-05-29 | $54.44 | 63,500 |
| 2026-05-28 | $54.21 | 11,200 |
| 2026-05-27 | $53.82 | 12,500 |
| 2026-05-26 | $53.55 | 16,100 |
| 2026-05-22 | $53.30 | 20,100 |
| 2026-05-21 | $53.80 | 19,200 |
| 2026-05-20 | $52.83 | 20,300 |
| 2026-05-19 | $50.92 | 24,700 |
About ALPS Medical Breakthroughs ETF
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
đ° Latest News
A Few Reasons Why Small-Cap ETFs Are Good Bets Now
Zacks âĸ 2026-04-09T12:00:00Z
ETF Winners & Losers of Q1 2026
Zacks âĸ 2026-04-02T15:00:00Z
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
Zacks âĸ 2026-01-06T16:00:00ZBiotech ETFs Hovering Around a 52-Week: Here's Why
Zacks âĸ 2025-10-30T13:00:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.